Hesse 2 New Class 1 Drugs New Progress Won the First New Product of the Year.

HSK7653 tablets are long-acting inhibitors of peptide-based peptidease-4 (DPP-4) and are a class 1 new drug developed by Hisshey with independent intellectual property rights to be used in the treatment of type 2 diabetes.
meters in-network data show that the current domestic has been approved for the listing of DPP-4 inhibitors have five, respectively, Siglitin, Shaglietine, Viglietin, Liglietine and Aglitin, the original drug has been approved for import for many years, the first imitation in 2019 and 2020 have been approved for listing.
Figure 1: Registration of HSK7653 domestic clinical trials Source: Miannet China Drug Clinical Trials Public Library HSK7653 tablets were approved for clinical trials in November 2017, Phase I clinical trials were conducted at Concord Hospital in Beijing in May 2018, Phase III clinical trial program recently obtained ethical approval from Peking University People's Hospital, and plans to begin screening patients in the fourth quarter of 2020.
HSK3486 emulsion injection is a new class of new drugs developed by Hesse with independent intellectual property rights, intended for surgical all-hemp induction, endoscopic sedation / anesthesia, ICU sedation and other adaptive disorders.
the product is the me-better of the classic narcotic drug propofol, which has the advantages of significantly reduced lipid dosage, basic no injection pain and wide safe dose. Figure
2: HSK3486 Lactobacular Injection Domestic Clinical Trial Registration Source: Minnet China Drug Clinical Trials Public Library HSK3486 Emulsion Injection has been registered in China 18 clinical trial studies, digestive endoscopic diagnosis and treatment of sedation and/or anesthesia, general anesthesia induced 2 phase III clinical and declared for listing, and are expected to be approved in 2020.
The application for phase III clinical trial for the adaptation "all-hemp maintenance" accepted by the State Drug Administration, if successful, will hopefully further broaden the product's adaptability and enhance market competitiveness.
Injected carpofen acetate net belongs to echinocytosis drugs, with a broad antibacterial spectrum, a long half-life, high binding rate with human serum protein, less adverse reactions, good patient tolerance and so on, is a clinically urgently needed anti-deep fungal infection drugs. According to
meters intranet data, in 2019 China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (china's public medical institutions) terminal injection carpofen net sales of more than 2 billion yuan, Haisk is the fourth of the same varieties to obtain a certificate of registration of domestic enterprises, the product is also the first haisk in 2020 to be approved for listing generic drugs.
source: In-net database, listed companies announcement Note: data statistics as of August 19, if there are omissions, welcome to point the right!